» Articles » PMID: 14739654

Genetic Vaccination of Mice with Plasmids Encoding the NS1 Non-structural Protein from Tick-borne Encephalitis Virus and Dengue 2 Virus

Overview
Journal Virus Genes
Date 2004 Jan 24
PMID 14739654
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Although there is a safe, inexpensive and efficacious vaccine against yellow fever, vaccination against other flavivirus diseases is less successful. There is no licensed vaccine against dengue fever and current vaccines against tick-borne encephalitis (TBE) and Japanese encephalitis are expensive and require several injections. Furthermore novel vaccines containing only virus envelope proteins may raise fears over antibody mediated enhancement (ADE) of disease. Here we report the successful use of genetic vaccination against TBE in an experimental animal model using a plasmid containing the coding sequence of a non-structural protein (NS1). Such vaccines would provide inexpensive protection against disease, without raising concerns over inducing ADE on subsequent exposure to heterotypic infectious virus. Attempts to generate chaemeric plasmids to protect against both TBE and dengue fever were less successful. Although these chaemeric plasmids directed the synthesis and secretion of the virus NS1 protein normally, no protection was observed against either TBE or dengue fever.

Citing Articles

Defining the "Correlate(s) of Protection" to tick-borne encephalitis vaccination and infection - key points and outstanding questions.

Ackermann-Gaumann R, Lang P, Zens K Front Immunol. 2024; 15:1352720.

PMID: 38318179 PMC: 10840404. DOI: 10.3389/fimmu.2024.1352720.


Activation of Early Proinflammatory Responses by TBEV NS1 Varies between the Strains of Various Subtypes.

Starodubova E, Tuchynskaya K, Kuzmenko Y, Latanova A, Tutyaeva V, Karpov V Int J Mol Sci. 2023; 24(2).

PMID: 36674524 PMC: 9863113. DOI: 10.3390/ijms24021011.


Dynamics of Whole Virus and Non-Structural Protein 1 (NS1) IgG Response in Mice Immunized with Two Commercial Tick-Borne Encephalitis Vaccines.

Salat J, Strakova P, Ruzek D Vaccines (Basel). 2022; 10(7).

PMID: 35891164 PMC: 9320558. DOI: 10.3390/vaccines10071001.


Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?.

Alves A, Costa S, Pinto P Front Med Technol. 2022; 3:640964.

PMID: 35047911 PMC: 8757892. DOI: 10.3389/fmedt.2021.640964.


Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and may Elicit NS1-Specific Antibody Responses in Vaccinated Individuals.

Salat J, Mikulasek K, Larralde O, Formanova P, Chrdle A, Haviernik J Vaccines (Basel). 2020; 8(1).

PMID: 32059489 PMC: 7157539. DOI: 10.3390/vaccines8010081.


References
1.
Cardosa M . Dengue vaccine design: issues and challenges. Br Med Bull. 1998; 54(2):395-405. DOI: 10.1093/oxfordjournals.bmb.a011696. View

2.
Peiris J, PORTERFIELD J . Antibody-dependent plaque enhancement: its antigenic specificity in relation to Togaviridae. J Gen Virol. 1982; 58(Pt 2):291-6. DOI: 10.1099/0022-1317-58-2-291. View

3.
Stephenson J . Genetically modified viruses: vaccines by design. Curr Pharm Biotechnol. 2001; 2(1):47-76. DOI: 10.2174/1389201013378815. View

4.
McCloud T, BRANDT W, RUSSELL P . Molecular size and charge relationships of the soluble complement-fixing antigens of dengue viruses. Virology. 1970; 41(3):569-72. DOI: 10.1016/0042-6822(70)90180-7. View

5.
Schmaljohn C, Custer D, VanderZanden L, Spik K, Rossi C, Bray M . Evaluation of tick-borne encephalitis DNA vaccines in monkeys. Virology. 1999; 263(1):166-74. DOI: 10.1006/viro.1999.9918. View